Press release
August 19, 2015

Evonik inaugurates applied technology laboratory dedicated to medical devices in Shanghai

Evonik Industries opened its first application technology laboratory for medical devices. Located in Shanghai, China, the laboratory will provide support to medical device manufacturers, who use Evonik polymers in their projects.

Evonik’s RESOMER® and RESOMER® Select brands offer a range of biodegradable polymers that are widely used in a variety of medical devices such as orthopedic screws, plates, etc. Implanted devices designed with RESOMER® resorb without a trace in the body over six months to two years, eliminating the need for secondary surgery to remove the devices.

"The market for medical devices is becoming increasingly important to our health care business, in particular in China, where we expect strong growth over the coming years," commented Dr. Jean-Luc Herbeaux, head of the Health Care Business Line in the Nutrition & Care segment.

"Players in this high growth market are looking for partners who can help them not only with reliable supply of materials but also with support on how to best use these materials for their specific design and production needs. With this new laboratory, we are now in a position to provide this support timely and locally."

Main activities are expected to include selection of the most suitable RESOMER® product for the application, characterization of production process conditions (injection-molding and extrusion) for successful design and scale-up, and finally manufacturing of technical samples for feasibility studies. "Our goal is to help our customers design and scale up medical devices faster," explains Herbeaux.

First customer projects will start in the coming weeks. New applied technology laboratories for medical devices are planned in other regions. Next planned opening is in Darmstadt, Germany to serve the European market.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavour to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.1 billion in 2014.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.